Phase III MIRASOL (GOG 3045/ENGOT-ov55) Study Results-Recording

Video Transcription

Video Summary

In this video presentation, Kathleen Moore, along with her co-chair Dr. Toon Van Gorp, provides a recap of the late-breaking abstract presented at the ASCO 2023 meeting on the Mirosol trial. The Mirosol trial is a randomized phase three clinical trial comparing mirvotoximab sort of tanzine (MST) versus investigator's choice chemotherapy for patients with platinum-resistant ovarian cancer that has high folate receptor alpha expression. It is revealed that mirvotoximab showed a significant improvement in overall survival, progression-free survival, and overall response rate compared to investigator's choice chemotherapy. The primary endpoint of progression-free survival showed a median of 5.62 months for MST, compared to 3.98 months for chemotherapy. Furthermore, the median overall survival for MST was 16.46 months, compared to 12.75 months for chemotherapy. The trial also demonstrated a differentiated safety profile for MST, with mainly low-grade gastrointestinal and ocular side effects. The data presented supports the use of MST as a new standard of care for platinum-resistant, folate receptor alpha-high expressing ovarian cancer.

Keywords

Mirosol trial

mirvotoximab sort of tanzine

MST

platinum-resistant ovarian cancer

overall survival

progression-free survival